12月23日，亨迪药业跌2.35%，成交额8800.87万元。两融数据显示，当日亨迪药业获融资买入额755.87 万元，融资偿还623.12万元，融资净买入132.75万元。截至12月23日，亨迪药业融资融券余额合计1.24 亿元。 融资方面，亨迪药业当日融资买入755.87万元。当前融资余额1.24亿元，占流通市值的2.39%，融资余 额低于近一年50%分位水平，处于较低位。 融券方面，亨迪药业12月23日融券偿还900.00股，融券卖出900.00股，按当日收盘价计算，卖出金额 1.12万元；融券余量2.23万股，融券余额27.74万元，超过近一年90%分位水平，处于高位。 资料显示，湖北亨迪药业股份有限公司位于湖北省荆门市掇刀区杨湾路122号，成立日期1995年12月29 日，上市日期2021年12月22日，公司主营业务涉及化学原料药及制剂产品的研发、生产和销售。主营业 务收入构成为：非甾体抗炎类68.06%，心血管类16.08%，其他8.86%，抗肿瘤类6.99%。 责任编辑：小浪快报 分红方面，亨迪药业A股上市后累计派现3.78亿元。近三年，累计派现3.06亿元。 机构持仓方面，截止2025年9月3 ...

Core Viewpoint - The Shenzhen Stock Exchange has decided to terminate the listing of ST Puli's stock and convertible bonds due to serious financial fraud issues, marking a significant change in the company's status in the capital market [4][5]. Financial Fraud and Consequences - ST Puli was found to have inflated its profits by a total of 669 million yuan, which accounted for 73.83% of the total reported profits for 2021 and 2022 [5][6]. - The company's core management, including the chairman and general manager, were involved in orchestrating the financial fraud, leading to severe penalties including a total fine of 24.2 million yuan and market bans for key executives [6][7]. Revenue Trends - In 2020, the company reported revenue of 1.189 billion yuan, a year-on-year increase of 25.10%, and a net profit of 407 million yuan, up 35.30% [6]. - Revenue continued to grow in 2021, reaching 1.509 billion yuan (up 26.94%), but net profit only slightly increased to 417 million yuan (up 2.25%) [6]. - In 2022, revenue rose to 1.619 billion yuan (up 7.31%), but net profit fell significantly to 295 million yuan, a decrease of 29.20% [6][7]. - By 2023, revenue dropped to 1.304 billion yuan, a decline of 19.43%, with net profit plummeting to 85.92 million yuan, down 70.87% [7]. Product Performance - The company's major products, particularly cardiovascular drugs, allergy medications, antibiotics, and digestive drugs, experienced significant revenue declines in 2023 [7]. - The overall business environment for ST Puli is deteriorating, with challenges expected to intensify in 2024, despite some products showing temporary growth [7]. Market Implications - The termination of ST Puli's listing serves as a warning to the pharmaceutical industry about the importance of compliance and maintaining core competitiveness to gain market trust [7].